FDA Issues Draft Guidance Clarifying Orange Book Patent Information Submission for NDA Holders
核心洞察
FDA published draft guidance on June 12, 2026, clarifying how NDA applicants and holders should submit patent information using Forms FDA 3542a (搜索) and 3542 for Orange Book listing.
The guidance distinguishes between Form 3542a for unapproved NDAs and Form 3542 for approved NDAs, with specific timelines including a 30-day submission window post-approval or patent issuance.
Key clarifications address method-of-use patent submissions, corrections to Use Codes, electronic submission procedures, and ongoing obligations for discontinued drug products.
The US Food and Drug Administration (FDA) released a draft guidance document on June 12, 2026, aimed at helping new drug application (NDA) applicants and holders navigate the submission of patent information for listing in the FDA's "Orange Book." Titled Forms FDA 3542a (搜索) and FDA 3542: Questions and Answers, the guidance provides clarity on which forms to use, when to submit them, and how to properly complete them.
The draft guidance distinguishes between two key forms. Form FDA 3542a is used when an NDA applicant submits information on a patent that claims a drug substance, drug product, or method of using the drug that is the subject of an unapproved original NDA, amendment, or supplement. Form FDA 3542, in contrast, is designated for NDA holders submitting the same information for an approved NDA or approved supplement.
"Form FDA 3542a must be used when an NDA applicant submits information on a patent that claims a drug substance (active ingredient), drug product (formulation or composition), or method of using the drug that is the subject of an unapproved original NDA, amendment to an NDA, or supplement to an NDA," the FDA stated. "Form FDA 3542 must be used when an NDA holder submits information on a patent that claims a drug substance (active ingredient), drug product (formulation or composition), or method of using the drug to that is the subject of an approved NDA or approved supplement to an NDA."
Submission Timelines and Requirements
The guidance outlines specific deadlines for patent information submission. NDA holders must submit the required patent information to the Orange Book within 30 days of receiving an NDA or NDA supplement approval. If a patent is issued after the NDA is approved, the NDA holder must submit Form FDA 3542 within 30 days of the patent's issuance. Should the FDA identify errors or omissions in the submitted form, the NDA holder will have 15 days to refile following agency notification.
NDA applicants and holders are required to submit information including the patent number and patent expiration date for each patent where a patent infringement could reasonably be asserted. For patents claiming only a polymorph that is the same as the active ingredient described by the NDA, the applicant or holder must certify that they have test data demonstrating the drug product containing the polymorph will perform the same as the drug product described in the NDA.
Key Clarifications in the Draft Guidance
The draft guidance addresses several procedural questions that have commonly arisen during the patent listing process.
Method-of-Use Patents: For patents that contain only method-of-use claims without any corresponding drug substance or drug product claims, the guidance clarifies that NDA holders may leave fields 2 (drug substance) and 3 (drug product) completely blank. For approved NDAs, the holder must also provide a description of each patented approved method of use, known as a "use code."
Correcting Use Codes: The guidance makes clear that NDA holders cannot simply modify an existing Use Code. Instead, they must expressly state their intention to "remove" the existing Use Code and "add" a new Use Code in field 1.h. This reflects agency policy that has been in place for several years.
Submission Procedures: Only NDA holders, or their agents, attorneys, or representatives, may submit Forms 3542a and 3542. While the patent owner — if different from the NDA applicant — may assist in completing and even signing the forms, only the NDA applicant may submit them to the FDA. The guidance also reminds NDA holders to submit forms electronically through the Electronic Submissions Gateway and not to send courtesy copies to the Orange Book staff or through other agency channels.
Discontinued Drug Products: For products that have been withdrawn from marketing but whose NDAs remain approved, the FDA reiterates that NDA holders have an ongoing obligation to submit patent information, including for newly issued patents.
Regulatory Context and Stakeholder Input
Orange Book patent listing is a statutory requirement under the Hatch-Waxman framework, and NDA holders must ensure regulatory compliance when submitting patent information to the FDA. The draft guidance does not, however, address more complex patent listing questions such as eligibility for listing and Use Code drafting, which often arise when preparing these forms.
Stakeholders may submit comments on the draft guidance through August 14, 2026, at www.regulations.gov under docket number FDA-2026-D-2698.